Gertjan M. Holtkamp

1.2k total citations
13 papers, 986 citations indexed

About

Gertjan M. Holtkamp is a scholar working on Immunology, Molecular Biology and Ophthalmology. According to data from OpenAlex, Gertjan M. Holtkamp has authored 13 papers receiving a total of 986 indexed citations (citations by other indexed papers that have themselves been cited), including 5 papers in Immunology, 4 papers in Molecular Biology and 4 papers in Ophthalmology. Recurrent topics in Gertjan M. Holtkamp's work include Glaucoma and retinal disorders (4 papers), Retinal Diseases and Treatments (4 papers) and Immune Response and Inflammation (3 papers). Gertjan M. Holtkamp is often cited by papers focused on Glaucoma and retinal disorders (4 papers), Retinal Diseases and Treatments (4 papers) and Immune Response and Inflammation (3 papers). Gertjan M. Holtkamp collaborates with scholars based in Netherlands, Belgium and Japan. Gertjan M. Holtkamp's co-authors include Aize Kijlstra, Alex F. de Vos, Ronald Peek, Antonella N. Witmer, Kari Alitalo, Taina A. Partanen, Reinier O. Schlingemann, Victor W.M. van Hinsbergh, Harriet G. T. Blaauwgeers and Marielle E. Kroon and has published in prestigious journals such as Journal of Clinical Oncology, Endocrinology and American Journal Of Pathology.

In The Last Decade

Gertjan M. Holtkamp

13 papers receiving 967 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Gertjan M. Holtkamp Netherlands 10 605 451 282 148 111 13 986
Samuel Shao-Min Zhang United States 15 661 1.1× 690 1.5× 393 1.4× 172 1.2× 72 0.6× 22 1.3k
Judit Baffi United States 17 958 1.6× 731 1.6× 435 1.5× 311 2.1× 95 0.9× 24 1.5k
Takao Tobe Japan 13 926 1.5× 731 1.6× 385 1.4× 73 0.5× 79 0.7× 29 1.3k
Shinsuke Miyahara Japan 14 662 1.1× 375 0.8× 374 1.3× 105 0.7× 124 1.1× 16 996
Svetlana Cherepanoff Australia 14 684 1.1× 312 0.7× 331 1.2× 104 0.7× 91 0.8× 45 892
Beth Coughlin United States 15 390 0.6× 305 0.7× 155 0.5× 246 1.7× 59 0.5× 18 710
Nitin Udar United States 25 526 0.9× 1.1k 2.5× 458 1.6× 123 0.8× 38 0.3× 58 1.8k
William Samuel United States 15 312 0.5× 573 1.3× 126 0.4× 124 0.8× 55 0.5× 27 912
Takazumi Taniguchi Japan 15 405 0.7× 257 0.6× 131 0.5× 49 0.3× 58 0.5× 25 660
Stephan Hoffmann Germany 13 333 0.6× 408 0.9× 176 0.6× 53 0.4× 33 0.3× 20 725

Countries citing papers authored by Gertjan M. Holtkamp

Since Specialization
Citations

This map shows the geographic impact of Gertjan M. Holtkamp's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Gertjan M. Holtkamp with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Gertjan M. Holtkamp more than expected).

Fields of papers citing papers by Gertjan M. Holtkamp

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Gertjan M. Holtkamp. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Gertjan M. Holtkamp. The network helps show where Gertjan M. Holtkamp may publish in the future.

Co-authorship network of co-authors of Gertjan M. Holtkamp

This figure shows the co-authorship network connecting the top 25 collaborators of Gertjan M. Holtkamp. A scholar is included among the top collaborators of Gertjan M. Holtkamp based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Gertjan M. Holtkamp. Gertjan M. Holtkamp is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

13 of 13 papers shown
1.
D’Hooghe, Thomas, Takao Fukaya, Yutaka Osuga, et al.. (2019). Efficacy and safety of ASP1707 for endometriosis-associated pelvic pain: the phase II randomized controlled TERRA study. Human Reproduction. 34(5). 813–823. 12 indexed citations
2.
Loriot, Yohann, Karim Fizazi, Robert J. Jones, et al.. (2014). Safety, tolerability and anti-tumour activity of the androgen biosynthesis inhibitor ASP9521 in patients with metastatic castration-resistant prostate cancer: multi-centre phase I/II study. Investigational New Drugs. 32(5). 995–1004. 54 indexed citations
3.
Nooten, Floortje van, Jean Paty, Celeste A. Elash, et al.. (2013). Development And Content Validity Of An Endometriosis Pain Daily Diary. Value in Health. 16(3). A76–A77. 1 indexed citations
4.
Boumans, Maria J H, J. G. A. Houbiers, Patrick Verschueren, et al.. (2011). Safety, tolerability, pharmacokinetics, pharmacodynamics and efficacy of the monoclonal antibody ASK8007 blocking osteopontin in patients with rheumatoid arthritis: a randomised, placebo controlled, proof-of-concept study. Annals of the Rheumatic Diseases. 71(2). 180–185. 36 indexed citations
5.
Baskin-Bey, Edwina, Gertjan M. Holtkamp, Matthew Ryan Smith, et al.. (2011). A phase II, open-label, single-arm, efficacy, and safety study of MDV3100 in patients with hormone-naïve prostate cancer.. Journal of Clinical Oncology. 29(7_suppl). 177–177. 3 indexed citations
6.
Holtkamp, Gertjan M., Aize Kijlstra, Ronald Peek, & Alex F. de Vos. (2001). Retinal Pigment Epithelium-immune System Interactions: Cytokine Production and Cytokine-induced Changes. Progress in Retinal and Eye Research. 20(1). 29–48. 217 indexed citations
7.
Blaauwgeers, Harriet G. T., Gertjan M. Holtkamp, Antonella N. Witmer, et al.. (1999). Polarized Vascular Endothelial Growth Factor Secretion by Human Retinal Pigment Epithelium and Localization of Vascular Endothelial Growth Factor Receptors on the Inner Choriocapillaris. American Journal Of Pathology. 155(2). 421–428. 425 indexed citations
8.
Holtkamp, Gertjan M., Alex F. de Vos, Aize Kijlstra, & Ron Peek. (1999). Expression of multiple forms of IL-1 receptor antagonist (IL-1ra) by human retinal pigment epithelial cells: identification of a new IL-1ra exon. European Journal of Immunology. 29(1). 215–224. 3 indexed citations
9.
Holtkamp, Gertjan M., et al.. (1999). Analysis of the secretion pattern of monocyte chemotactic protein-1 (MCP-1) and transforming growth factor-beta 2 (TGF-β2) by human retinal pigment epithelial cells. Clinical & Experimental Immunology. 118(1). 35–40. 58 indexed citations
10.
Holtkamp, Gertjan M., Alex F. de Vos, Aize Kijlstra, & Ron Peek. (1999). Expression of multiple forms of IL‐1 receptor antagonist (IL‐1ra) by human retinal pigment epithelial cells: identification of a new IL‐1ra exon. European Journal of Immunology. 29(1). 215–224. 23 indexed citations
11.
Holtkamp, Gertjan M., et al.. (1998). Polarized secretion of IL-6 and IL-8 by human retinal pigment epithelial cells. Clinical & Experimental Immunology. 112(1). 34–43. 130 indexed citations
12.
Schotanus, K., Gertjan M. Holtkamp, Nico van Rooijen, Fred J.H. Tilders, & F. Berkenbosch. (1995). Circulating tumor necrosis factor-alpha does not mediate endotoxin-induced hypothermia in rats. American Journal of Physiology-Regulatory, Integrative and Comparative Physiology. 268(4). R989–R996. 9 indexed citations
13.
Schotanus, K., Gertjan M. Holtkamp, Rob H. Meloen, et al.. (1995). Domains of rat interleukin 1 beta involved in type I receptor binding.. Endocrinology. 136(1). 332–339. 15 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026